Article Text

Download PDFPDF

2022-RA-937-ESGO Rucaparib MAintenance after bevacizumab maintenance following carboplatin based chemotherapy in primary ovarian cancer
  1. Elena-Ioana Braicu1,
  2. Klaus Pietzner1,
  3. Jessica Dysarz2,
  4. Gunther Rogmans3,
  5. Pauline Wimberger4,5,
  6. Eva Egger6,
  7. Jens Gerber7,
  8. Michael Eichbaum8,
  9. Florian Heitz9,
  10. Tomas Kupec10,
  11. Martin Christoph Koch11,
  12. Mustafa Deryal12,
  13. Ralf Witteler13,
  14. Antje Sperfeld14,
  15. Oliver Tomé15,
  16. Barbara Schmalfeldt16,
  17. Frederik Marmé17,
  18. Bastian Czogalla18 and
  19. Jalid Sehouli1
  1. 1Klinik für Gynäkologie, Charité Universitätsmedizin Berlin, Berlin, Germany
  2. 2North-Eastern German Society of Gynecological Oncology, Berlin, Germany
  3. 3ZAGO – am Helios Klinikum Krefeld, Krefeld, Germany
  4. 4Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany
  5. 5Nationales Centrum für Tumorerkrankungen Dresden, Dresden, Germany
  6. 6Gynäkologie und Gynäkologische Onkologie, Universitätsklinikum Bonn, Bonn, Germany
  7. 7Frauenheilkunde und Geburtshilfe, Städtisches Klinikum Dessau, Dessau, Germany
  8. 8Klinik für Frauenheilkunde und Geburtshilfe, Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany
  9. 9Gynäkologie and Gynäkologische Onkologie, Kliniken Essen-Mitte, Essen, Germany
  10. 10Clinic for gynaecology and obstetrics, RWTH Aachen, Aachen, Germany
  11. 11Department of Obstetrics and Gynecology, ANregiomed Ansbach Hospital, Ansbach, Germany
  12. 12Department for Gynecology and Obstetrics, CaritasKlinikum Saarbrücken St. Theresia, Saarbrücken, Germany
  13. 13Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Münster, Münster, Germany
  14. 14Gynäkologie, Helios Klinikum Berlin-Buch, Berlin, Germany
  15. 15Klinik für Gynäkologie und Geburtshilfe, St. Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany
  16. 16Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
  17. 17Medizinische Fakultät Mannheim, Universität Heidelberg, Universitätsklinikum Mannheim, Mannheim, Germany
  18. 18Department of Obstetrics and Gynecology, University Hospital, LMU Munich, München, Germany


Introduction/Background Ovarian cancer (OC) is the fifth most common cause of death from cancer in women in Europe, with most patients being diagnosed in advanced stages. The most common histological subtype is high grade serous OC, which is characterised by deficiency in homologous recombination. The current standard therapy for advanced OC patients is debulking surgery, followed by platinum based chemotherapy and bevacizumab (bev), followed by maintenance therapy with bev or monotherapy with PARP inhibitors (PARPi). The anticancer effects of PARPi seem to be increased by the addition of antiangiogenic drugs. Preclinical data showed increased HRD in tumours pre-treated with bev, and clinical trials showed a benefit of the combination of antiangiogenic drugs and PARPi vs. PARPi alone. Hence, in this placebo-controlled study we will evaluate rucaparib maintenance following bevacizumab maintenance for the treatment of advanced primary high grade BRCAwt OC (centrally tested by NGS analysis).

Methodology This study will randomise 190 patients with histologically confirmed advanced (FIGO stage IIIA- IV) high grade serous or high grade endometrioid OC, fallopian tube cancer, primary peritoneal cancer or clear cell carcinoma of the ovary at the ration of 2:1 to receive either rucaparib 600 mg BID or placebo as maintenance therapy following first line chemotherapy with 6 cycles of Carboplatin/Paclitaxel and at least 12 months of bevacizumab. Subsequent maintenance therapy with rucaparib will continue for 24 months or until disease progression, unacceptable toxicity, or withdrawal. Randomisation is stratified by surgery planned time point (neoadjuvant vs. adjuvant), surgical outcome (R0 vs R1), response to chemotherapy followed by bev (CR/NED vs. PR/SD) and study center. Primary endpoint is PFS per RECIST v1.1. Secondary endpoints are PFS2, quality of life, daily activity, time to next medical intervention, time to next subsequent therapy, safety assessments and OS. So far 35 patients are randomised in the study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.